News and Announcements
EDITORIAL
Challenges in immunotherapy for colorectal cancer: Perspectives from the immune microenvironment
Show Less
1 Tianjin Key Laboratory of Modern Chinese Medicine Theory of Innovation and Application, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin,
China
2 Department of General Practice, Tianjin Hospital of Integrated Traditional Chinese and Western Medicine (Nankai Hospital), Tianjin,
China
EJMO, 026050047 https://doi.org/10.36922/EJMO026050047
Received: 26 January 2026 | Accepted: 2 March 2026 | Published online: 10 April 2026
(This article belongs to the Special Issue Tumor Immune Microenvironment and Intervention Strategies)
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Conflict of interest
Xianbin Kong is the Editorial Board Member of this journal and Guest Editor of this special issue, but was not in any way involved in the editorial and peer-review process conducted for this paper, directly or indirectly. Separately, other authors declared that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
References
- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi: 10.3322/caac.21834
- Lin X, Zong C, Zhang Z, Fang W, Xu P. Progresses in ers for cancer immunotherapy. MedComm. 23;4(5):e387. doi: 10.1002/mco2.387
- Yang C, Guo S, Ye K, et al. A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity. Nat Biomed Eng. Published online January 22, 2025. doi: 10.1038/s41551-025-01569-4
- de Torres CS, Elias E, Vaghi C, et al. Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer. Cancer Treat Rev. 2026;143:103089. doi: 10.1016/j.ctrv.2026.103089
- Lenz HJ, Parikh A, Spigel DR, et al. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: Phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 2024;12(3):e008409. doi: 10.1136/jitc-2023-008409
- Fakih M, Raghav KPS, Chang DZ, et al. Regorafenib plus nivolumab in patients with mismatch repair- proficient/microsatellite stable metastatic colorectal cancer: A single-arm, open-label, multicentre phase 2 study. EClinicalMedicine. 2023;58:101917. doi: 10.1016/j.eclinm.2023.101917